PD-L1在不同亚型三阴性乳腺癌中的表达及与患者预后的相关性分析
The Expression of PD-L1 in Different Molecular Subtypes of Triple-Negative Breast Cancer and Its Correlation with Prognosis
DOI: 10.12677/ACM.2023.13112471, PDF,   
作者: 王晓玮:青岛大学医学院,山东 青岛;孔 滨*:青岛大学附属医院乳腺外科,山东 青岛
关键词: 乳腺癌三阴性乳腺癌预后PD-L1分子分型Breast Cancer Triple-Negative Breast Cancer Prognosis PD-L1 Molecular Subtype
摘要: 目的:探讨分析细胞程序性死亡–配体1 (PD-L1)在不同亚型三阴性乳腺癌组织中的表达及与患者预后的相关性。方法:选择240名接受根治性切除前未行新辅助治疗的三阴性乳腺癌(TNBC)患者进行PD-L1表达的免疫组化结果分析,其中四种亚型的TNBC患者各60例。使用Kaplan-Meier、单变量和多变量Cox比例风险模型分析来比较不同亚型PD-L1表达与患者生存时间的关系。结果:中位随访时间为55.75个月(范围:23.28~120.02个月)。与PD-L1阴性的TNBC患者相比,PD-L1阳性的TNBC患者的总生存期(OS)明显增加(P = 0.029)。在不同分型的TNBC组织中PD-L1表达率最高的是免疫调节型(IM)为26.7%,伴随其较好的预后。而不同的临床分期(TNM分期)、组织学分级、有无淋巴结转移在不同分型的TNBC中PD-L1的阳性表达率存在显著差异性(P < 0.05),其中IM在四种亚型的TNBC患者中OS明显延长。单因素Cox比例模型分析表明,PD-L1是TNBC的独立预后因素。结论:PD-L1在不同分型的TNBC中对预后的影响不同,其中在IM分型中与预后的关系最密切。
Abstract: Objective: To investigate the expression of PD-L1 in different subtypes of triple-negative breast cancer and its correlation with the prognosis of patients. Methods: A total of 240 patients with tri-ple-negative breast cancer (TNBC) who had not received neoadjuvant therapy before radical resec-tion were selected for immunohistochemical study of PD-L1 expression, including 60 patients with four subtypes of TNBC. Kaplan-Meier and univariate Cox proportional hazard model analysis were used to compare the relationship between PD-L1 expression and survival time of patients with dif-ferent subtypes. Results: The median follow-up time was 55.75 months (range: 23.28~120.02 months). Overall survival (OS) was significantly increased in PD-L1-positive TNBC patients com-pared with PD-L1-negative TNBC patients (P = 0.029). Among the different types of TNBC tissues, the highest expression rate of PD-L1 was 26.7% in immunomodulatory type (IM), which was ac-companied by a better prognosis. There were significant differences in the positive expression rate of PD-L1 among different types of TNBC with different TNM stages, histological grades, and lymph node metastasis (P < 0.05), and OS was significantly prolonged in the four subtypes of TNBC patients with IM. Univariate Cox proportional model analysis showed that PD-L1 was an independent prog-nostic factor for TNBC. Conclusion: PD-L1 has different effects on prognosis in different types of TNBC, and the relationship between PD-L1 and prognosis is most close in IM type.
文章引用:王晓玮, 孔滨. PD-L1在不同亚型三阴性乳腺癌中的表达及与患者预后的相关性分析[J]. 临床医学进展, 2023, 13(11): 17625-17631. https://doi.org/10.12677/ACM.2023.13112471

参考文献

[1] Azim, H.A., Shohdy, K.S., Elghazawy, H., et al. (2022) Programmed Death-Ligand 1 (PD-L1) Expression Predicts Re-sponse to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Bi-omarkers, 27, 764-772. [Google Scholar] [CrossRef
[2] Ji, P., Gong, Y. and Hu, X. (2019) Role of PD-1/PD-L1 in Microenvironment of Breast Cancer. Chinese Journal of Oncology, 41, 401-405.
[3] Yuan, K.Y., Wu, J.P., Zhao, Y.J., et al. (2022) Consistent Expression of PD-L1 in Tumor Microenvironment with Peripheral PD-1/PD-L1 in Circulating T Lymphocytes of Operable Breast Cancer: A Diagnostic Test. Diagnostic Pathology, 17, Article No. 68. [Google Scholar] [CrossRef] [PubMed]
[4] Oner, G., Önder, S., Karatay, H., et al. (2021) Clinical Impact of PD-L1 Expression in Triple-Negative Breast Cancer Patients with Residual Tumor Burden after Neo-adjuvant Chemotherapy. World Journal of Surgical Oncology, 19, Article No. 264. [Google Scholar] [CrossRef] [PubMed]
[5] Mori, H., Kubo, M., Yamaguchi, R., et al. (2017) The Combina-tion of PD-L1 Expression and Decreased Tumor-Infil- trating Lymphocytes Is Associated with a Poor Prognosis in Tri-ple-Negative Breast Cancer. Oncotarget, 8, 15584-15592. [Google Scholar] [CrossRef] [PubMed]
[6] Chu, J., Yeo, M.-K., Lee, S.H., et al. (2022) Clinicopathological and Prognostic Significance of Programmed Death Ligand-1 SP142 Expression in 132 Patients with Triple-Negative Breast Cancer. In Vivo, 36, 2890-2898. [Google Scholar] [CrossRef] [PubMed]
[7] Purwanto, I., Heriyanto, D.S., Ghozali, A., et al. (2020) Overexpres-sion of Programmed Death-Ligand 1 Receptor mRNA as an Independent Negative Prognostic Factor for Triple Negative Breast Cancer. World Journal of Oncology, 11, 216-222. [Google Scholar] [CrossRef] [PubMed]
[8] Zhang, M.H., Sun, H.B., Zhao, S., et al. (2017) Expression of PD-L1 and Prognosis in Breast Cancer: A Meta-Analysis. Oncotarget, 8, 31347-31354. [Google Scholar] [CrossRef] [PubMed]
[9] Yoshikawa, K., Ishida, M., Yanai, H., et al. (2021) Prognostic Significance of PD-L1-Positive Cancer-Associated Fibroblasts in Patients with Triple-Negative Breast Cancer. BMC Cancer, 21, Article No. 239. [Google Scholar] [CrossRef] [PubMed]
[10] Yazaki, S., Shimoi, T., Yoshida, M., et al. (2023) Integrative Prognostic Analysis of Tumor-Infiltrating Lymphocytes, CD8, CD20, Programmed Cell Death-Ligand 1, and Tertiary Lymphoid Structures in Patients with Early-Stage Triple- Negative Breast Cancer Who Did Not Receive Adjuvant Chem-otherapy. Breast Cancer Research and Treatment, 197, 287-297. [Google Scholar] [CrossRef] [PubMed]
[11] Cerbelli, B., Pernazza, A., Botticelli, A., et al. (2017) PD-L1 Ex-pression in TNBC: A Predictive Biomarker of Responseto Neoadjuvant Chemotherapy? Biomed Research International, 2017, Article ID: 1750925. [Google Scholar] [CrossRef] [PubMed]
[12] Guo, L., Li, W.B., Zhu, X.X., et al. (2016) PD-L1 Expression and CD274 Gene Alteration in Triple-Negative Breast Cancer: Implication for Prognostic Biomarker. SpringerPlus, 5, Article No. 805. [Google Scholar] [CrossRef] [PubMed]
[13] Stovgaard, E.S., Bokharaey, M., List-Jensen, K., et al. (2020) PD-L1 Diagnostics in the Neoadjuvant Setting: Implications of Intratumoral Heterogeneity of PD-L1 Expression in Triple Negative Breast Cancer for Assessment in Small Biopsies. Breast Cancer Research and Treatment, 181, 553-560. [Google Scholar] [CrossRef] [PubMed]
[14] Tomioka, N., Azuma, M., Ikarashi, M., et al. (2018) The Ther-apeutic Candidate for Immune Checkpoint Inhibitors Elucidated by the Status of Tumor-Infiltrating Lymphocytes (TILs) and Programmed Death Ligand 1 (PD-L1) Expression in Triple Negative Breast Cancer (TNBC). Breast Cancer, 25, 34-42. [Google Scholar] [CrossRef] [PubMed]
[15] Wang, H., Ding, X.-H., Liu, C.-L., et al. (2023) Genomic Alterations Impacting Tumor-Infiltrating Lymphocytes and PD-L1 Expression Patterns in Triple-Negative Breast Cancer. JNCI-Journal of the National Cancer Institute, djad154. [Google Scholar] [CrossRef] [PubMed]
[16] Pan, B.J., Xu, C., Ping, G.Q., et al. (2017) Correlation Analysis of PD-L1 Expression and Prognosis in Triple-Negative Breast Cancers. Chinese Journal of Pathology, 46, 822-826.
[17] Dieci, M.V., Tsvetkova, V., Griguolo, G., et al. (2020) Integration of Tumour Infiltrating Lymphocytes, Programmed Cell-Death Ligand-1, CD8 and FOXP3 in Prognostic Models for Triple-Negative Breast Cancer: Analysis of 244 Stage I-III Patients Treated with Standard Therapy. European Journal of Cancer, 136, 7-15. [Google Scholar] [CrossRef] [PubMed]
[18] Suzuki, K., Ohe, R., Kabasawa, T., et al. (2023) Histological Spatial Analysis on the Induction of PD-L1+ Macrophages by CD8+ T Cells at the Marginal Microenvironment of Tri-ple-Negative Breast Cancer. Breast Cancer, 30, 1094-1104. [Google Scholar] [CrossRef] [PubMed]
[19] Lotfinejad, P., Kazemi, T., Mokhtarzadeh, A., et al. (2020) PD-1/PD-L1 Axis Importance and Tumor Microenvironment Immune Cells. Life Sciences, 259, Article ID: 118297. [Google Scholar] [CrossRef] [PubMed]
[20] Zhang, M.L., Song, J., Yang, H.G., et al. (2022) Efficacy and Safety of PD-1/PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Acta Oncologica, 61, 1105-1115. [Google Scholar] [CrossRef